These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19597022)

  • 1. Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
    Pirl WF; Solis J; Greer J; Sequist L; Temel JS; Lynch TJ
    J Clin Oncol; 2009 Aug; 27(23):e49-50; author reply e51. PubMed ID: 19597022
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis from erlotinib: a case report.
    Moscetti L; Nelli F; Ruggeri EM
    Tumori; 2011; 97(3):415-6. PubMed ID: 21789026
    [No Abstract]   [Full Text] [Related]  

  • 4. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
    Bunn PA
    J Clin Oncol; 2007 Jun; 25(18):2504-5. PubMed ID: 17577025
    [No Abstract]   [Full Text] [Related]  

  • 5. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 7. Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Van Sebille YZ; Gibson RJ; Wardill HR; Bowen JM
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):152-6. PubMed ID: 27035390
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
    Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
    Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib or gefitinib for non-small-cell lung cancer.
    Yusuf SW; Kim P; Durand JB
    N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675910
    [No Abstract]   [Full Text] [Related]  

  • 10. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acneiform reaction to erlotinib.
    Schalock PC; Zug KA
    Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM; Spiro TP; Daw HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
    Gandara DR; Gumerlock PH
    J Clin Oncol; 2005 Sep; 23(25):5856-8. PubMed ID: 16043825
    [No Abstract]   [Full Text] [Related]  

  • 14. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling.
    Frankfort BJ; Garibaldi DC
    Ophthalmic Plast Reconstr Surg; 2007; 23(6):496-7. PubMed ID: 18030130
    [No Abstract]   [Full Text] [Related]  

  • 15. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract]   [Full Text] [Related]  

  • 16. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
    Lacouture ME; Hwang C; Marymont MH; Patel J
    J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
    [No Abstract]   [Full Text] [Related]  

  • 17. Palmar bullous blistering induced by erlotinib.
    Berg A; Brustugun OT; Lund-Iversen M; Helland Å
    J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 20. Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
    Laterza MM; Chiurazzi B; Brangi M; Riccardi F; Cartenì G
    Tumori; 2013; 99(1):3e-5e. PubMed ID: 23549019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.